Background. We examined whether observed increases in antibiotic nonsusceptible nonvaccine serotypes after introduction of pneumococcal conjugate vaccine in the United States in 2000 were driven primarily by vaccine or antibiotic use.
7-valent pneumococcal conjugate vaccine (PCV7) in the United States in 2000, the proportion of penicillin-nonsusceptible and macrolide-nonsusceptible isolates from invasive disease was increasing [3] [4] [5] . Previous studies have correlated differential use of antimicrobials with different rates of nonsusceptibility across geographic areas, as well as changing patterns of usage and nonsusceptibility over time [6] [7] [8] [9] [10] [11] .
When PCV7 was introduced, the 7 serotypes included in the vaccine accounted for 78% of penicillin-nonsusceptible strains [3] . In the decade since, rates of disease caused by these 7 serotypes declined by 99%, and serotypes not included in PCV7 have increased significantly, a phenomenon known as serotype replacement. Some of the replacing serotypes (eg, 19A, 15A, 23A, 35B, 6C) have shown high and/or increasing levels of antimicrobial nonsusceptibility, raising the question of whether antimicrobial use may in part be responsible for the increased prevalence [12] [13] [14] .
In the pre-PCV7 era, geographic differences in proportions of nonsusceptibility to penicillin and macrolides resulted from geographic variation in selective pressure for nonsusceptibility [10, 15] . In pneumococci, selective pressure may affect nonsusceptibility in 2 ways: by increasing the prevalence of nonsusceptibility within each serotype, and/or by increasing the prevalence of serotypes in which the prevalence of nonsusceptibility is high. The frequencies of pneumococcal serotypes within a population reflect multiple selective pressures imposed by natural and vaccine-induced host immunity [16] , and it is in principle possible that selection by antimicrobial use may also affect this pattern. In the pre-PCV7 era, no evidence of such an effect was found; the impact of differences in antimicrobial selective pressure was seen solely in varying prevalence of nonsusceptibility within each serotype, but not in variations in the prevalence of the more nonsusceptible serotypes [15] . Understanding the interplay between antimicrobial use pressures and changing serotype distributions has important policy implications for both antimicrobial stewardship and vaccination programs. In this study, we assessed geographical, serotype, and temporal variation in the frequency of drug nonsusceptibility, with a particular focus on the question of whether, contrary to pre-PCV7 observations, there was evidence that geographic variation in the intensity of selective pressure for nonsusceptibility was reflected in greater prevalence of nonsusceptible serotypes.
METHODS

Population
We used active surveillance for IPD collected during 2000-2009 through the Active Bacterial Core surveillance (ABCs) system, a collaboration between the Center for Disease Control and Prevention and several state health departments and academic institutions in the United States. ABCs is a populationand laboratory-based system currently operating in part or all of 10 states: California, Colorado (added in 2001), Connecticut, Georgia, Maryland, Minnesota, New Mexico (added in 2004), New York, Oregon, and Tennessee. Demographic data are collected for all cases. Isolates, which are available for approximately 85%-90% of cases, are serotyped and tested for antimicrobial nonsusceptibility [17, 18] .
Macrolides and β-lactams are important antibiotic classes for the treatment of IPD. We therefore focused our analysis on penicillin (an important marker for β-lactams) and erythromycin (a macrolide). Pneumococcal isolates were tested for penicillin and erythromycin susceptibility using broth microdilution. For the purposes of our analyses, strains categorized as intermediate or resistant according to the Clinical and Laboratory Standards Institute [19] were grouped into a single "nonsusceptible" category. By grouping intermediate and fully resistant isolates, we were able to observe overarching trends in resistance, without losing power to detect differences (as would have been the case if each category was analyzed separately). Penicillin-nonsusceptible strains were those with a minimum inhibitory concentration of ≥0.12 µg/mL; erythromycin-nonsusceptible strains were those with a minimum inhibitory concentration of ≥0.5 µg/mL. The meningitis breakpoints for penicillin resistance were chosen as these are lower than the nonmeningitis breakpoints and therefore allow greater sensitivity for detection of small increases in minimum inhibitory concentrations. Dually nonsusceptible isolates were those nonsusceptible to both penicillin and erythromycin.
Geographic Differences
If nonsusceptibility is due to differing use of antibiotics across sites, we would expect that within-site nonsusceptibility patterns in 1 serotype would be correlated with nonsusceptibility patterns in other serotypes in the same site [15, 20] . To determine whether this was the case, we calculated Spearman rank correlation coefficients, C, separately for the proportion nonsusceptible to penicillin, erythromycin, and both by site, for each pair of the 8 most common serotypes from 2007 to 2009. Each row and column corresponds to a serotype pair, and each entry c ij represents the correlation between the nonsusceptible proportions of serotypes i and j. Within each site, we generated three 8-by-8 matrices of C ij , 1 for penicillin nonsusceptibility, 1 for erythromycin nonsusceptibility, and 1 for strains that were nonsusceptible to both penicillin and erythromycin. Using the sum of C as a test statistic, we assessed nonrandom overall correlation between serotypes by site. Significance was assessed by a permutation test [15] .
Geographic Standardization
Similar to the McCormick et al analysis of prevaccine data [15] , we used 2 standardizations to assess to what extent site-specific differences in the prevalence of nonsusceptibility were attributable to differences in serotype distribution-the proportions of IPD caused by individual serotypes-and to differences in serotype-specific prevalence of nonsusceptibility [15] . To understand how the relationship between serotype distribution and proportions nonsusceptible within serotype has changed in the postvaccine era, we repeated the standardization for 2 time periods: 2002-2006 and 2007-2009 . We chose these periods because previously published data suggested that nonsusceptibility decreased during the former period and increased during the later period [21] . To allow for accurate comparison with the results from McCormick et al, we used only those ABCs sites under continuous surveillance since 1998. We first calculated crude proportions nonsusceptibility for each of the 8 sites for penicillin-nonsusceptibility, erythromycin-nonsusceptibility, and dual-nonsusceptibility. Next, 2 different methods were used to calculate the standardized proportions nonsusceptibility for each site, using the following formula [15] :
where R i is the standardized nonsusceptible proportion for site i. In Standardization 1, the effects of geographical differences in serotype distribution are removed by standardizing the serotype distribution of each individual site to that of the entire population, while maintaining within-serotype nonsusceptibility prevalence by site. In this standardization, p j is the population's proportion of isolates that are serotype j, and r ij is the prevalence of nonsusceptibility among isolates of serotype j at site i. In Standardization 2, the effects of geographical differences in nonsusceptibility within serotype are removed by standardizing the prevalence of nonsusceptibility within each site to that of the entire population, while maintaining site-specific serotype distributions [15] . In this standardization, p j is the population's prevalence of nonsusceptibility among isolates of serotype j and r ij is the proportion of isolates from site i that are serotype j. Both standardizations were repeated 3 times, once each for penicillin, erythromycin, and dual nonsusceptibility. Initially, we performed these standardizations separately for pediatric (<5 years old) and older cases. Because results were similar, we combined these groups into a single analysis (see Supplementary Tables 1 and 2 ).
As was done by McCormick et al [15] , we used weighted linear regression to examine the relationship between the standardized and crude proportions nonsusceptible. A regression slope of 1 would indicate that the crude and standardized proportions are identical and that the standardizing factor (eg, within-site serotype distribution or within-site and withinserotype proportion nonsusceptible) is not responsible for geographic differences. A regression slope of zero would indicate that the standardizing factor is completely responsible for the geographic differences.
Temporal Analysis
To understand the effects of PCV7 on nonsusceptibility, we performed weighted logistic regression 3 times, with penicillin-, erythromycin-, or dual-nonsusceptibility as the dependent variable and culture date as the independent variable, with an interaction term indicating whether the case was from the pre-or post-PCV7 periods. To allow comparisons to previous work and for this temporal analysis only, the comparison group included cases with isolates susceptible to both penicillin and erythromycin (eg, the penicillin model compared penicillinnonsusceptible isolates to isolates susceptible to both penicillin and erythromycin) [15] . Each case was assigned a weight based on its culture year and serotype, calculated as the proportion of serotype j over the entire study period (1998-2009) divided by the proportion of serotype j within year i. Similar to the standardizations described above, this inverse-probability weighting was designed to remove temporal changes in serotype distribution (due, for example, to vaccine effects) and assess the trends in overall prevalence of nonsusceptibility that were attributable to changing prevalence of nonsusceptibility within each serotype. The regression coefficient is a measure of the rate of change in the prevalence of nonsusceptibility over time [15, 22] , and the associated odds ratio measures the increase in odds of nonsusceptibility over 1 year. Differences in the regression coefficient between periods indicate different rates of increase of nonsusceptibility in different periods, even when adjusting for changing serotype distribution (ie, the direct effects of the vaccine).
Analyses were conducted using SAS, version 9.2 software (SAS Institute). Data were collected as part of routine public health surveillance and, therefore, the analysis was exempt from human subjects review.
RESULTS
Prevalence of Nonsusceptibility: Pre-PCV7 Versus Post-PCV7
In the prevaccine era (1998-1999), 26% of isolates in ABCs were nonsusceptible to penicillin (range, 14% in California to 43% in Tennessee), 18% were nonsusceptible to erythromycin (range, 8% in California to 31% in Tennessee), and 15% were nonsusceptible to both (range, 5% in New York to 28% in Tennessee). After an initial decrease in penicillin nonsusceptibility during 2000-2006, rates returned to pre-PCV7 levels of about 25% (range, 13% in Oregon to 31% in Georgia), remaining stable during [2007] [2008] [2009] . By 2007 By -2009 , erythromycin nonsusceptibility increased somewhat over the pre-PCV7 levels to 25% overall (range, 9% in Oregon to 32% in Georgia) and dual nonsusceptibility increased to 18% overall (range, 6% in Oregon to 24% in Georgia).
Geographic Variation in Nonsusceptibility
Within-serotype nonsusceptibility varied widely across states during 2007-2009, and those states with a higher prevalence of nonsusceptibility in one serotype tended to have a higher prevalence of nonsusceptibility in others (Table 1) . Penicillin nonsusceptibility was present in every state for serotypes 6C, 15A, 19A, and 23A, with Tennessee having the highest prevalence of nonsusceptibility in 6C and 19A and the second highest prevalence of nonsusceptibility in serotype 15A. Georgia was the only state to have some level of penicillin nonsusceptibility within all 8 of the most common serotypes, and Tennessee had nonsusceptibility in 7 out of 8 serotypes. Levels of erythromycin nonsusceptibility were generally higher across states and serotypes than penicillin nonsusceptibility. Tennessee had the highest level of erythromycin nonsusceptibility for 4 out of 8 serotypes and the second highest level in an additional 2 serotypes. Serotype 15A was highly nonsusceptible in every state, with the lowest proportion of nonsusceptibility at 40% in Oregon.
The sum of the Spearman correlation coefficients for each pair of serotypes by site was significantly positive for penicillin (C = 21.97; P = .002), erythromycin (C = 25.05; P = .001), and both (C = 25.15; P = .001), indicating that sites with high proportions of nonsusceptibility in any serotype tended to have high proportions in other serotypes as well.
Nature of Geographic Variation in Nonsusceptibility
In the early post-PCV7 period (2002) (2003) (2004) (2005) (2006) , geographic differences in nonsusceptibility were almost entirely attributable to variation in the proportion nonsusceptible within each serotype, with minimal differences between sites in the frequency of serotypes that are commonly nonsusceptible (Table 2) . Sites retained most of their variation in the prevalence of nonsusceptibility after removing geographic differences in serotype distribution (Standardization 1). For Standardization 2, removing geographic differences in within-serotype nonsusceptibility proportions removed nearly all geographic variation in the prevalence of nonsusceptibility. These effects are quantified by regressing standardized versus crude prevalence of nonsusceptibility: regression slopes for Standardization 1 were near 1 (with confidence intervals including 1 for erythromycin-and dualnonsusceptibility), whereas regression slopes for Standardization 2 were nearly zero (with confidence intervals including zero for erythromycin-and dual-nonsusceptibility; see Table 2 ).
In the later PCV7 period (2007-2009), for penicillin nonsusceptibility, evidence suggests that serotype distribution played a role in the geographic variation in prevalence of nonsusceptibility. When geographic differences in serotype distribution were removed (Standardization 1), geographic differences in prevalence of nonsusceptibility were reduced (regression slope of 0.57 [95% confidence interval {CI}, .14-1.00] between crude and standardized), while when geographic differences in the prevalence of nonsusceptibility within each serotype were removed (Standardization 2), some geographic variation in nonsusceptibility persisted (regression slope of 0.52 [95% CI, .11-93]; see Table 2 ).
These regression slopes, however, were not statistically significantly different from those in the pre-PCV7 or early post-PCV7 periods. For erythromycin-and dual-nonsusceptibility, geographic variation was largely attributable to differences in within-serotype nonsusceptibility prevalence rather than serotype distribution, although confidence intervals for the regression slope for Standardization 2 did not cross zero.
Rate of Increase in Nonsusceptible Strains with Time
Using logistic regression, we measured the rate of increase in penicillin-nonsusceptible, erythromycin-nonsusceptible, and dually nonsusceptible pneumococci, relative to strains susceptible to both drugs, per year after standardizing the changing serotype distribution over time; this regression measured the within-serotype changes in nonsusceptibility while removing the effects of changing serotype distribution. For penicillin, there was no indication that the rate of increase in the prevalence of nonsusceptibility was different in the pre-versus post-PCV7 period. The odds ratio (corresponding to the increase per year in the odds that an isolate is penicillin-nonsusceptible vs susceptible) for the pre-PCV7 period (1998-1999) was 1.03/ y (95% CI, .94-1.14) compared to 1.06/y (95% CI, 1.05-1.07) in the post-PCV7 period (Table 3 ). For both erythromycin and dual nonsusceptibility, however, the odds ratios were significantly lower in the post-PCV7 period ( for dual nonsusceptibility) with the odds ratio in the post-PCV7 period indicating a continued but slower increase in nonsusceptibility, even while controlling for changing serotype distribution.
DISCUSSION
Changing nonsusceptibility patterns in S. pneumoniae isolates have broad implications for both the prevention and treatment of IPD. Prior to PCV7 introduction, the prevalence of nonsusceptibility varied geographically, and variation in the prevalence of nonsusceptibility within each serotype almost entirely accounted for this overall variation [15] . Coupled with antimicrobial use data [10] , these observations suggested that geographic differences within the United States in the prevalence of nonsusceptibility reflected variation in selective pressure imposed by antimicrobial use, and that the main impact of antimicrobial use was to select for nonsusceptible strains within each serotype, rather than to alter the distribution of serotypes. The introduction of PCV7 altered nonsusceptibility patterns by reducing IPD from vaccine types (which tended to be among the most nonsusceptible) [15, 23] , increasing IPD from nonvaccine types, which were more likely to be susceptible [12, 13, 24] , and also, perhaps, via reductions in antimicrobial use [25, 26] .
The present analysis found that in the early (2002) (2003) (2004) (2005) (2006) and late (2007-2009) post-PCV7 periods, geographic differences in the prevalence of nonsusceptibility persisted, and that these still reflected variation in the prevalence of nonsusceptibility within each serotype, which tended to be high in certain sites (Georgia and Tennessee) for all serotypes, and lower in other sites (California, Maryland, and Oregon) for all serotypes. However, by the late post-PCV7 period, there was some evidence that highnonsusceptibility sites also tended to have higher proportions of the serotypes that are most likely to be penicillin nonsusceptible. While the differences between the pre-and post-PCV7 period shown in Table 3 are not statistically significant, the change in serotype distribution toward increasing prevalence of nonsusceptibility within serotypes in the states with already high prevalences of nonsusceptibility suggests that antimicrobial selective pressure may affect the serotype distribution present in a particular population. A previous mathematical model suggested that antimicrobial use might play a role in promoting serotype replacement, because one of the most important nonvaccine replacement types was 19A, which is also highly nonsusceptible [27] . That conclusion has been debated [28] , in part because of the prior lack of evidence that antimicrobial use affects serotype distribution [15] . While our analysis continues to find little evidence of such effects in the early post-PCV7 period, it suggests that serotype prevalence in the late post-PCV7 period may have been moving toward more penicillin-nonsusceptible serotypes in certain areas with the highest selective pressure. Nonsusceptibility was more widespread across the most common serotypes in the prevaccine era, whereas nonsusceptibility in recent years is limited to a few of the most common serotypes, perhaps allowing serotype distribution to play a more substantial role in overall nonsusceptibility.
Our temporal analyses addressed the change in prevalence of strains nonsusceptible to penicillin, erythromycin, or both, relative to strains sensitive to both drugs. Penicillin-nonsusceptible strains in the pre-PCV7 era were increasing very slowly relative to susceptible strains (and declining relative to erythromycinnonsusceptible or dually nonsusceptible strains), and this pattern continued in the post-PCV7 era once serotype distribution was standardized. That is, after accounting for the effect of PCV7 in reducing serotypes most likely to be nonsusceptible and causing increases in serotypes that tended to be susceptible, there was no change in the trajectory of penicillin-nonsusceptible strains. For erythromycin-nonsusceptible and dually nonsusceptible strains, again after accounting for the change in serotypes over time, there was a marked slowing in the upward trajectory of nonsusceptibility in the post-PCV7 era relative to the pre-PCV7 era. At least 2 interpretations are possible. PCV7 use and other changes over time may have reduced selective pressure for erythromycin-and dual-nonsusceptibility, slowing the increase of these strains [29] . Alternatively or in addition, the prevalence of b Std-2 removes the effects of site-specific differences in within-serotype resistance proportion and supports the role of antibiotics in the selection for resistance. nonsusceptibility may have plateaued for other reasons, as has been observed even without vaccination for penicillin and erythromycin nonsusceptibility in many populations [30] . The first explanation is testable in part by examining trends in antimicrobial use before and after PCV7 introduction. Among the 8 most common serotypes, the only nonsusceptible serotype found in both the pre-PCV7 era and recent years was serotype 19A. This serotype has remained highly nonsusceptible to both penicillin and erythromycin and has increased in the proportion nonsusceptible in all states, with the exception of erythromycin in Oregon. Because serotype 19A is included in the recently-licensed PCV13, it is likely that nonsusceptibility trends will change in the coming years as IPD due to serotype 19A becomes less common.
We did not have access to antibiotic prescribing data and therefore are unable to definitively conclude whether antibiotic usage influences the distribution of serotypes over space and time. However, our findings do not suggest a major role of antibiotic use as a driver for serotype replacement, especially in the early post-PCV7 years. Rather, PCV7 likely selects for non-PCV7 serotypes (ie, serotype replacement) which, under continued antibiotic pressure, develop nonsusceptibility.
Our findings add to already existing evidence that antibiotic use is an important factor influencing nonsusceptibility in S. pneumoniae. The decrease in PCV7 serotypes and resulting drop in overall crude proportions nonsusceptible has been offset by increases in proportions nonsusceptible within serotypes. The introduction of PCV13 is likely to result in substantial decreases in IPD due to highly nonsusceptible serotypes such as 19A, which will likely have the effect of reducing overall nonsusceptibility, at least temporarily. However, given our past experience with serotype replacement and the already high levels of nonsusceptibility in certain non-PCV13 serotypes (eg, 6C, 15A, 23A, and 35B), it seems likely that nonsusceptibility will continue to be a problem in the future, one best addressed by appropriate use of antibiotics [14] .
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